8. Any cardiac pre-excitation syndromes, e.g. Wolff-Parkinson-White syndrome. 9. Active drug or alcohol use or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements 10. Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical (i.e. infectious disease) illness must not be enrolled into this study. 11. Any illness or condition that in the opinion of the investigator may affect the safety of the subject or the evaluation of any study endpoint. 12. Any other conditions judged by the investigator that would limit the evaluation of a subject. 4.3 Subject Recruitment and Screening Subjects will be identified through the clinical practices of the co -investigators or sub- investigators in the Division of Medical Oncology , Division of Radiation Oncology and Division of Otolaryngology at the Hospi tal of the University of Pennsylvania and its affiliated hospitals and through referrals from outside hospitals and physicians. The trial will be publicized on the 29 Date: 8 April 2016 v 2.1 INO-3112 UPCC # 39313 / Inovio HPV -005 Inovio Pharmaceuticals, Inc Clinical Protocol website of the Abramson Cancer Center of the Hospital of the University of Pennsylvania. Thi s protocol will also be listed in ClinicalTrials.gov database.